Curaleaf CEO: Regulatory Patchwork and Restructuring Pressures Are Defining Today’s Cannabis Market

Success in today’s cannabis industry increasingly depends on understanding and navigating a maze of conflicting regulations. With rules on products, licensing and compliance varying sharply from state to state, operators face significant hurdles in maintaining consistency across markets. At the same time, emerging international frameworks highlight just how uneven the U.S. regulatory landscape has become.

Boris Jordan, CEO of multistate operator and international cannabis powerhouse Curaleaf, discussed these challenges at the recent IgniteIt Capital & Policy Summit in Washington, D.C. Sitting down for a morning keynote with Jack Mascone, head of capital markets for Seaport Global Securities, Jordan outlined key regulatory differences between the U.S. and European cannabis markets.

https://youtu.be/Ofz6ja61j40?si=8Wxr-imp78G9Tkj2

“The biggest difference between the European regulatory environment and the U.S. regulatory environment [is that] the European markets didn’t have the sort of unfair incarceration,” said Jordan, “so they don’t have the same social equity pressures that the U.S. does.”

He noted that the emphasis on social equity initially created misunderstandings, but as operators and regulators worked through those early disconnects, dialogue improved and relationships strengthened.

Jordan also pointed to the challenge of each U.S. state having its own rules governing products, marketing, packaging and more. He said operators are now working toward standardizing regulations across jurisdictions to ease operations and improve predictability.

By contrast, Curaleaf’s operations in Germany fall under a pharmaceutical license. The federal government regulates the company directly, and the rules apply consistently across the entire country — a level of clarity he characterized as far easier to manage than the patchwork of U.S. state laws.

Mascone then asked how these regulatory differences shape Curaleaf’s internal culture. Jordan said the legal and cultural context matters both for the company and for consumers.

“In the U.S., it’s both something for entertaining and for casual use, and a lot of people do use it for medical purposes. But it does make a difference in two different cultures.”

“In Europe,” he continued, “we almost operate as a pharmaceutical [company] — it is dramatically different than the U.S. environment, where we operate as a consumer products company.”

The conversation then turned to the federal ban on hemp THC products included in the recently approved spending bill. Jordan said the ban will have limited impact on Curaleaf, noting the company’s small investment in the hemp THC beverage space. He added that the moment presents an opportunity for hemp and regulated cannabis advocates to align in pushing for broader reform.

“I think this is a time when, finally, everyone needs to get together to lobby the government on an overall reform package around the plant,” he said, “to get one piece of transparent legislation around the various cannabinoids.”

An Industry in Transition

Mascone next raised the wave of liquidation, receivership, restructuring and acquisition taking place across the U.S. cannabis sector. Jordan said the trend is common in new, fast-growing industries and reflects a maturing market.

“I think it’s a natural progression of a developing, emerging industry,” he said.

Despite consolidation pressure, Jordan emphasized that Curaleaf sees value in helping social equity operators and other independents survive in a difficult landscape. As key customers of Curaleaf’s wholesale business, those operators are integral to the company’s model.

“Curaleaf has launched a program where we’re working with social equity licensees and with independents and teaching them inventory management, teaching them how to run their businesses, teaching them how to assort their stores, how to price their products, so that they can be successful. Because at the end of the day, they’re our customers,” Jordan explained. “We’re a brand company that sells products to independent dispensaries as well as other MSOs, and we want these companies to be successful. So, we’re going to work with them, and we want to try to get them to be as successful as we possibly can.”

The discussion closed with Mascone noting that investors remain hesitant to deploy new capital into the cannabis industry without federal clarity. Jordan agreed, citing regulatory instability as a core impediment.

“The biggest problem this industry has right now is a stable capital source and one that’s actually economical, and that has largely to do with the absolute madness of the regulatory environment between federal and state in the sector,” he said.